Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Incyte Corporation
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Pfizer
Incyte Corporation
Tizona Therapeutics, Inc
Genentech, Inc.
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Bristol-Myers Squibb
Fate Therapeutics
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Pfizer
Ono Pharmaceutical Co. Ltd
Shanghai Zhongshan Hospital
Fate Therapeutics
Massachusetts General Hospital
Eli Lilly and Company
Innovent Biologics (Suzhou) Co. Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
West China Hospital
Curegenix Inc.
Eli Lilly and Company
Lund University Hospital
National Institutes of Health Clinical Center (CC)
Dragonboat Biopharmaceutical Company Limited
M.D. Anderson Cancer Center
Georgetown University
Novartis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Yale University
Genentech, Inc.
Bristol-Myers Squibb
Vanderbilt University Medical Center
University of Chicago
Genentech, Inc.